Educational Modules: New Tools for Atopic Dermatitis Clinical Investigators

The International Eczema Council provides Atopic Dermatitis (AD) clinical investigators with valuable updated educational modules for atopic dermatitis (AD) assessment training.  

These IEC-provided tools can help investigators improve data quality and study accuracy by reducing interrater variability.

The modules use a standardized method to calculate:

  • BSA: the percentage of body surface area affected in four regions
  • EASI: the patient’s Eczema Area Severity Index score, an evaluation of area involvement and clinical signs
  • TLSS: the Target Lesion Severity Score, which assesses severity of lesions

With real-life examples using photos and an experienced investigator’s tips, these modules provide investigators with a broad overview of the rating process and detailed instructions on each method, and include helpful guidance on evaluating patients with darker skin tones as well as recommendations for using these assessments in clinical trials. Even skilled medical professionals who routinely perform clinical assessments will benefit.

These atopic dermatitis modules are hosted for the IEC on an external site by WCG Clinical, with certified training also available. Recertification by reviewing training modules and completing associated quizzes is recommended every two (2) years.

Read more about the Validated Investigator Global Assessment for Atopic Dermatitis (VIGA-AD™) scale. 


Access the VIGA-AD™  Scale



Medscape Education

The Atopic Dermatitis Learning Center: Riding the Next Wave

Atopic dermatitis (AD) is a chronic inflammatory skin disorder that affects 5% to 30% of children and 1% to 10% of adults globally. It is characterized by recurrent eczematous lesions and intense itch and can have a severe impact on quality of life. Numerous agents that target the immunological mechanism of AD are under investigation in pediatric and adult patients. It is imperative that clinicians have the most recent data to provide optimal outcomes for their patients with AD.

Learn More